AtriCure (NASDAQ:ATRC) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 3 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.17, a high estimate of $55.00, and a low estimate of $45.00. Experiencing a 5.54% decline, the current average is now lower than the previous average price target of $54.17.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Lowers | Buy | $53.00 | $64.00 |
| Danielle Antalffy | UBS | Lowers | Buy | $55.00 | $60.00 |
| Daniel Stauder | Citizens | Lowers | Market Outperform | $52.00 | $60.00 |
| Marie Thibault | BTIG | Maintains | Buy | $54.00 | $54.00 |
| Mike Matson | Needham | Maintains | Buy | $45.00 | $45.00 |
| Lilia-Celine Lozada | JP Morgan | Raises | Overweight | $48.00 | $42.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AtriCure's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on AtriCure analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into AtriCure's Background
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
AtriCure: Financial Performance Dissected
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AtriCure's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 15.84%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AtriCure's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): AtriCure's ROE excels beyond industry benchmarks, reaching -0.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AtriCure's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: AtriCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.